Trump administration announces drug pricing deals with Teva, Astellas and others
The agreements expand the administration’s most-favored-nation pricing program to 26 companies and cover 89% of the branded drug market, the White House said.
- On Monday, President Donald Trump announced voluntary 'most-favored-nation' pricing agreements with nine mid-sized pharmaceutical firms, expanding the program to 26 manufacturers covering 90% of the domestic branded drug market.
- Trump launched the MFN policy via a May 12, 2025, executive order to align U.S. drug costs with international prices, crediting his 'America First' trade policy for compelling companies to invest in domestic production.
- These nine companies committed to invest at least $19.6 billion in U.S. manufacturing, while four firms agreed to donate 290 metric tons of active pharmaceutical ingredients to a federal strategic reserve to reduce foreign supply reliance.
- The administration projects the deals will save Americans more than $600 billion, though Public Citizen's Peter Maybarduk, access to medicines director, argued there is 'no evidence' companies followed through on prior commitments.
- Trump indicated the remaining 10% of the pharmaceutical market will have 'no choice' but to join the program, while the administration continues promoting TrumpRx, which officials claim has saved consumers more than $700 million since February.
51 Articles
51 Articles
Trump Announces New Drug Pricing Deals With Nine Manufacturers
WASHINGTON D.C (VINnews) — President Trump said Monday that he has reached new voluntary pricing agreements with nine pharmaceutical companies, expanding an administration effort to bring U.S. prescription drug prices closer to those charged in other wealthy countries. The companies are Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi, […]
Trump announces deals with nine more drugmakers to cut U.S. prices
WASHINGTON — President Donald Trump announced Monday that nine additional drugmakers have agreed to sell medicines in the United States at “most-favored-nation” prices matching the lowest rates paid in other wealthy countries, expanding a signature effort he says will cut costs for Medicaid programs, cash-paying patients and future drug launches. The White House said the… The post Trump announces deals with nine more drugmakers to cut U.S. price…
Trump administration announces drug pricing deals with Teva, Astellas and others
U.S. President Donald Trump announced a new round of drug-pricing agreements with international pharmaceutical companies and some smaller biotechs on Monday, part of a push to make healthcare more affordable for Americans.
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
